KULWANT BUTTAR: Open Payments
NPI 1366486789 · BUFFALO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$731 in 14 payments from 8 companies in 2025. Trend: 2023 $225 · 2024 $441 · 2025 $731
Food & beverage: $731
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $164 |
| Janssen Scientific Affairs, LLC | 1 | $131 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| ABBVIE INC. | 1 | $125 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| Neurocrine BioSciences, Inc. | 2 | $55 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
Products named: INVEGA SUSTENNA, FANAPT, VRAYLAR, LYBALVI, ABILIFY ASIMTUFII, INGREZZA, ARISTADA, ERZOFRI EXTENDED-RELEASE.
Industry payments across NY — which companies pay providers there.
